Drug developer Zogenix Inc. (Nasdaq: ZGNX) plans to sell its common stock to raise $56 million after the company’s accountant raised concerns about Zogenix’s ability to continue without liquidation.

The San Diego-based company develops and commercializes medications for people with central nervous system and pain-related conditions. Ernst & Young LLP, Zogenix’s accountant, raised substantial doubt about the company’s ability to continue as a going concern, or without the threat of liquidation in March because of the company’s losses and lack of capital.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.